

## **Extracellular iron diminishes anticancer effects of vitamin C: An *in vitro* study**

Marija Mojić,<sup>1</sup> Jelena Bogdanović Pristov,<sup>2</sup> Danijela Maksimović-Ivanić,<sup>1</sup> David R. Jones,<sup>3</sup> Marina Stanić,<sup>2</sup> Sanja Mijatović,<sup>1</sup> Ivan Spasojević<sup>2\*</sup>

<sup>1</sup>*Department of Immunology, Institute for Biological Research "Siniša Stanković", University of Belgrade, Despot Stefan Blvd. 142, 11060 Belgrade, Serbia,* <sup>2</sup>*Department of Life Sciences, Institute for Multidisciplinary Research, University of Belgrade, Kneza Višeslava 1, 11030 Belgrade, Serbia,* <sup>3</sup>*Inositide Laboratory, Cancer Research UK Manchester Institute, University of Manchester, Manchester, M20 4BX, UK.*

\*Correspondence to:

Ivan Spasojević, Institute for Multidisciplinary Research, University of Belgrade, Kneza Višeslava 1, 11030 Belgrade, Serbia, Phone: +381 11 2078459, Fax: +381 11 3055289, E-mail: redoxsci@gmail.com

**Table S1.** Concentration of iron and relative viability of cancer cells exposed to ascorbate in plasma samples obtained from six volunteers.

| Volunteer                            | 1                                  | 2                                  | 3                                  | 4                                  | 5                                  | 6                                  |
|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
| <b>Fe (<math>\mu\text{M}</math>)</b> | <b>13.74 <math>\pm</math> 1.36</b> | <b>12.52 <math>\pm</math> 1.85</b> | <b>17.80 <math>\pm</math> 3.06</b> | <b>16.91 <math>\pm</math> 1.45</b> | <b>27.95 <math>\pm</math> 3.40</b> | <b>21.52 <math>\pm</math> 1.09</b> |
| Asc (mM)                             | Viability of LNCaP (MTT)           |                                    |                                    |                                    |                                    |                                    |
| 0                                    | 1.00 $\pm$ 0.05                    | 1.00 $\pm$ 0.03                    | 1.00 $\pm$ 0.03                    | 1.00 $\pm$ 0.07                    | 1.00 $\pm$ 0.03                    | 1.00 $\pm$ 0.06                    |
| 5                                    | 0.96 $\pm$ 0.06                    | 0.93 $\pm$ 0.06                    | 1.03 $\pm$ 0.03                    | 1.02 $\pm$ 0.03                    | 0.99 $\pm$ 0.07                    | 1.04 $\pm$ 0.05                    |
| 10                                   | 0.94 $\pm$ 0.13                    | 0.78 $\pm$ 0.11*                   | 0.93 $\pm$ 0.06*                   | 0.93 $\pm$ 0.08                    | 0.96 $\pm$ 0.08                    | 1.01 $\pm$ 0.03                    |
| Asc (mM)                             | Viability of LNCaP (CV)            |                                    |                                    |                                    |                                    |                                    |
| 0                                    | 1.00 $\pm$ 0.03                    | 1.00 $\pm$ 0.05                    | 1.00 $\pm$ 0.02                    | 1.00 $\pm$ 0.01                    | 1.00 $\pm$ 0.04                    | 1.00 $\pm$ 0.06                    |
| 5                                    | 0.90 $\pm$ 0.01                    | 0.91 $\pm$ 0.05                    | 1.06 $\pm$ 0.06                    | 0.98 $\pm$ 0.04                    | 0.94 $\pm$ 0.04                    | 1.04 $\pm$ 0.07                    |
| 10                                   | 0.85 $\pm$ 0.15                    | 0.74 $\pm$ 0.11*                   | 0.95 $\pm$ 0.05                    | 0.82 $\pm$ 0.04*                   | 0.90 $\pm$ 0.05*                   | 0.94 $\pm$ 0.04                    |
| Asc (mM)                             | Viability of PC3 (MTT)             |                                    |                                    |                                    |                                    |                                    |
| 0                                    | 1.00 $\pm$ 0.07                    | 1.00 $\pm$ 0.03                    | 1.00 $\pm$ 0.04                    | 1.00 $\pm$ 0.12                    | 1.00 $\pm$ 0.07                    | 1.00 $\pm$ 0.11                    |
| 5                                    | 1.13 $\pm$ 0.11                    | 1.03 $\pm$ 0.05                    | 1.04 $\pm$ 0.03                    | 1.13 $\pm$ 0.11                    | 0.96 $\pm$ 0.03                    | 1.10 $\pm$ 0.05                    |
| 10                                   | 1.01 $\pm$ 0.04                    | 0.98 $\pm$ 0.07                    | 1.00 $\pm$ 0.07                    | 1.05 $\pm$ 0.13                    | 0.97 $\pm$ 0.10                    | 1.00 $\pm$ 0.05                    |
| Asc (mM)                             | Viability of PC3 (CV)              |                                    |                                    |                                    |                                    |                                    |
| 0                                    | 1.00 $\pm$ 0.04                    | 1.00 $\pm$ 0.06                    | 1.00 $\pm$ 0.04                    | 1.00 $\pm$ 0.04                    | 1.00 $\pm$ 0.01                    | 1.00 $\pm$ 0.05                    |
| 5                                    | 1.05 $\pm$ 0.06                    | 0.96 $\pm$ 0.03                    | 0.95 $\pm$ 0.01                    | 1.07 $\pm$ 0.08                    | 1.09 $\pm$ 0.01                    | 1.16 $\pm$ 0.06                    |
| 10                                   | 0.94 $\pm$ 0.08                    | 0.94 $\pm$ 0.07                    | 0.95 $\pm$ 0.08                    | 0.89 $\pm$ 0.08                    | 1.11 $\pm$ 0.06                    | 1.03 $\pm$ 0.04                    |

\* - significant ( $p < 0.05$ ) compared to control (0 mM ascorbate)